Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biochem Pharma (BCHE) -- Ignore unavailable to you. Want to Upgrade?

To: Steve Childs who wrote (207)	1/8/1998 8:06:00 AM
From: biodoc	Respond to of 783

Once again, Viracept is a protease inhibitor while 3-TC is a reverse transcriptase inhibitor. Current therapy for HIV consists of a three (at least) drug combination with one protease inhibitor and two reverse transcriptase inhibitors. Viracept and 3-TC are NOT competing drugs. Neither drug has any place as a single agent. Most but not all combinations include 3-TC. Of the protease inhibitors, Viracept is gaining market share over Merck's drug, Crixivan, but not at the expense of 3-TC (since they are not the same class of drug).

To: Steve Childs who wrote (207)	1/9/1998 6:21:00 PM
From: Todd D. Wiener	Read Replies (1) \| Respond to of 783

Biotechs See Strong Sales Boosting 4Q Earnings Dow Jones Newswires BioChem Pharma Inc. (BCHE) saw a dramatic rebound in sales of its AIDS drug 3TC, or Epivir, in the quarter, according to Silverman. He predicts sales rose 20% in the fourth quarter compared with the third quarter. The expected rise was helped in part by Glaxo Wellcome PLC's (GLX) launching of its Combivir drug, a combination of BioChem's 3TC and Glaxo's Retrovir, at the end of September. Analysts expect BioChem, of Laval, Quebec, to have earned 16 cents a share in the latest period, up from 14 cents a share a year ago, according to First Call.